Evidence map›Paper›PMID 34063505›Full record

ReviewMolecules (Basel, Switzerland)2021

The Therapeutic Potential of Psilocybin.

Henry Lowe, Ngeh Toyang, Blair Steele, Henkel Valentine, Justin Grant, Amza Ali, Wilfred Ngwa, Lorenzo Gordon

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 9 pooled it
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 9 syntheses or guidelines pooled it, 229 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.Journal of psychopharmacology (Oxford, England) · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Mechanisms of psilocybin on the treatment of posttraumatic stress disorder.Journal of psychopharmacology (Oxford, England) · 2026
    Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Henry LoweBiotech R & D Institute, University of the West Indies, Mona 99999, Jamaica.
Ngeh ToyangVilotos Pharmaceuticals Inc., Baltimore, MD 21202, USA.ORCID 0000-0001-9683-6192
Blair SteeleBiotech R & D Institute, University of the West Indies, Mona 99999, Jamaica.
Henkel ValentineBiotech R & D Institute, University of the West Indies, Mona 99999, Jamaica.
Justin GrantBiotech R & D Institute, University of the West Indies, Mona 99999, Jamaica.
Amza AliBiotech R & D Institute, University of the West Indies, Mona 99999, Jamaica.
Wilfred NgwaBrigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Lorenzo GordonCaribbean School of Medical Sciences, Kingston 99999, Jamaica.
University of the West Indies System · JMBrigham and Women's Hospital · USUniversity of Maryland, Baltimore · USUniversity of the Commonwealth Caribbean · JM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The psychedelic effects of some plants and fungi have been known and deliberately exploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal source of naturally occurring psychedelics. The mushroom extract, psilocybin has historically been used as a psychedelic agent for religious and spiritual ceremonies, as well as a therapeutic option for neuropsychiatric conditions. Psychedelic use was largely associated with the "hippie" counterculture movement, which, in turn, resulted in a growing, and still lingering, negative stigmatization for psychedelics. As a result, in 1970, the U.S. government rescheduled psychedelics as Schedule 1 drugs, ultimately ending scientific research on psychedelics. This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as psilocybin. A 2004 pilot study from the University of California, Los Angeles, exploring the potential of psilocybin treatment in patients with advanced-stage cancer managed to reignite interest and significantly renewed efforts in psilocybin research, heralding a new age in exploration for psychedelic therapy. Since then, significant advances have been made in characterizing the chemical properties of psilocybin as well as its therapeutic uses. This review will explore the potential of psilocybin in the treatment of neuropsychiatry-related conditions, examining recent advances as well as current research. This is not a systematic review.

Indexed as

Biomedical ResearchClinical Studies as TopicHallucinogensHumansMental DisordersMolecular StructureNeoplasmsPsilocybinHallucinogensPsilocybinaddictionanxietycancerdepressionmagic mushroomsneuropharmaceuticalsneurotherapeuticspsilocybinpsychedelicpsychopharmacology

Identifiers

PMID34063505
PMCPMC8156539
OpenAlexW3161556967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.